Literature DB >> 18636552

Role of the hemopexin domain of matrix metalloproteinases in cell migration.

Antoine Dufour1, Nicole S Sampson, Stanley Zucker, Jian Cao.   

Abstract

The biological functions of matrix metalloproteinases (MMPs) extend beyond extracellular matrix degradation. Non-proteolytic activities of MMPs are just beginning to be understood. Herein, we evaluated the role of proMMPs in cell migration. Employing a Transwell chamber migration assay, we demonstrated that transfection of COS-1 cells with various proMMP cDNAs resulted in enhancement of cell migration. Latent MMP-2 and MMP-9 enhanced cell migration to a greater extent than latent MMP-1, -3, -11 and -28. To examine if proteolytic activity is required for MMP-enhanced cell migration, three experimental approaches, including fluorogenic substrate degradation assay, transfection of cells with catalytically inactive mutant MMP cDNAs, and addition of hydroxamic acid-derived MMP inhibitors, were employed. We demonstrated that the proteolytic activities of MMPs are not required for MMP-induced cell migration. To explore the mechanism underlying MMP-enhanced cell migration, structure-function relationship of MMP-9 on cell migration was evaluated. By using a domain swapping approach, we demonstrated that the hemopexin domain of proMMP-9 plays an important role in cell migration when examined by a transwell chamber assay and by a phagokinetic migration assay. TIMP-1, which interacts with the hemopexin domain of proMMP-9, inhibited cell migration, whereas TIMP-2 had no effect. Employing small molecular inhibitors, MAPK and PI3K pathways were found to be involved in MMP-9-mediated cell migration. In conclusion, we demonstrated that MMPs utilize a non-proteolytic mechanism to enhance epithelial cell migration. We propose that hemopexin homodimer formation is required for the full cell migratory function of proMMP-9.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18636552      PMCID: PMC2574584          DOI: 10.1002/jcp.21535

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  45 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion.

Authors:  N Ramos-DeSimone; E Hahn-Dantona; J Sipley; H Nagase; D L French; J P Quigley
Journal:  J Biol Chem       Date:  1999-05-07       Impact factor: 5.157

3.  The propeptide domain of membrane type 1 matrix metalloproteinase is required for binding of tissue inhibitor of metalloproteinases and for activation of pro-gelatinase A.

Authors:  J Cao; M Drews; H M Lee; C Conner; W F Bahou; S Zucker
Journal:  J Biol Chem       Date:  1998-12-25       Impact factor: 5.157

4.  Membrane type matrix metalloproteinase 1 activates pro-gelatinase A without furin cleavage of the N-terminal domain.

Authors:  J Cao; A Rehemtulla; W Bahou; S Zucker
Journal:  J Biol Chem       Date:  1996-11-22       Impact factor: 5.157

5.  Characterization of the monomeric and dimeric forms of latent and active matrix metalloproteinase-9. Differential rates for activation by stromelysin 1.

Authors:  M W Olson; M M Bernardo; M Pietila; D C Gervasi; M Toth; L P Kotra; I Massova; S Mobashery; R Fridman
Journal:  J Biol Chem       Date:  2000-01-28       Impact factor: 5.157

6.  Antagonism of Rho-kinase stimulates rat penile erection via a nitric oxide-independent pathway.

Authors:  K Chitaley; C J Wingard; R Clinton Webb; H Branam; V S Stopper; R W Lewis; T M Mills
Journal:  Nat Med       Date:  2001-01       Impact factor: 53.440

Review 7.  Matrix metalloproteinases: structures, evolution, and diversification.

Authors:  I Massova; L P Kotra; R Fridman; S Mobashery
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

Review 8.  Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.

Authors:  S Zucker; J Cao; W T Chen
Journal:  Oncogene       Date:  2000-12-27       Impact factor: 9.867

Review 9.  Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.

Authors:  S Zucker; M Hymowitz; C Conner; H M Zarrabi; A N Hurewitz; L Matrisian; D Boyd; G Nicolson; S Montana
Journal:  Ann N Y Acad Sci       Date:  1999-06-30       Impact factor: 5.691

10.  Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis.

Authors:  S Zucker; C Conner; B I DiMassmo; H Ende; M Drews; M Seiki; W F Bahou
Journal:  J Biol Chem       Date:  1995-10-06       Impact factor: 5.157

View more
  58 in total

1.  Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.

Authors:  Albert G Remacle; Vladislav S Golubkov; Sergey A Shiryaev; Russell Dahl; John L Stebbins; Andrei V Chernov; Anton V Cheltsov; Maurizio Pellecchia; Alex Y Strongin
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 2.  Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.

Authors:  Merry L Lindsey; Rogelio Zamilpa
Journal:  Cardiovasc Ther       Date:  2010-07-14       Impact factor: 3.023

Review 3.  Key metalloproteinase-mediated pathways in the kidney.

Authors:  Tammo Ostendorf; Andreas Ludwig; Justyna Wozniak; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2021-04-20       Impact factor: 28.314

4.  Cell-specific expression of the transcriptional regulator RHAMM provides a timing mechanism that controls appropriate wound re-epithelialization.

Authors:  Cornelia Tolg; Muhan Liu; Katelyn Cousteils; Patrick Telmer; Khandakar Alam; Jenny Ma; Leslie Mendina; James B McCarthy; Vincent L Morris; Eva A Turley
Journal:  J Biol Chem       Date:  2020-03-12       Impact factor: 5.157

5.  miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14.

Authors:  Yiyi Li; Cem Kuscu; Anna Banach; Qian Zhang; Ashleigh Pulkoski-Gross; Deborah Kim; Jingxuan Liu; Eric Roth; Ellen Li; Kenneth R Shroyer; Paula I Denoya; Xiaoxia Zhu; Longhua Chen; Jian Cao
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

6.  Matrix metalloproteinase-19 promotes metastatic behavior in vitro and is associated with increased mortality in non-small cell lung cancer.

Authors:  Guoying Yu; Jose D Herazo-Maya; Tomoko Nukui; Marjorie Romkes; Anil Parwani; Brenda M Juan-Guardela; Jennifer Robertson; Jack Gauldie; Jill M Siegfried; Naftali Kaminski; Daniel J Kass
Journal:  Am J Respir Crit Care Med       Date:  2014-10-01       Impact factor: 21.405

7.  A Flavonoid Glycoside Compound from Murraya paniculata (L.) Interrupts Metastatic Characteristics of A549 Cells by Regulating STAT3/NF-κB/COX-2 and EGFR Signaling Pathways.

Authors:  Qing Shi; Zhou Jiang; Jingyi Yang; Yunlong Cheng; Yaqiong Pang; Ning Zheng; Jiahang Chen; Wenge Chen; Lee Jia
Journal:  AAPS J       Date:  2017-08-25       Impact factor: 4.009

8.  Neutrophil granulocyte derived MMP-9 is a VEGF independent functional component of the angiogenic switch in pancreatic ductal adenocarcinoma.

Authors:  Dirk Bausch; Thomas Pausch; Tobias Krauss; Ulrich Theodor Hopt; Carlos Fernandez-del-Castillo; Andrew L Warshaw; Sarah P Thayer; Tobias Keck
Journal:  Angiogenesis       Date:  2011-03-26       Impact factor: 9.596

9.  The hemopexin domain of MMP3 is responsible for mammary epithelial invasion and morphogenesis through extracellular interaction with HSP90β.

Authors:  Ana Luísa Correia; Hidetoshi Mori; Emily I Chen; Fernando C Schmitt; Mina J Bissell
Journal:  Genes Dev       Date:  2013-04-01       Impact factor: 11.361

10.  Expression and function of matrix metalloproteinase (MMP)-28.

Authors:  Ursula R Rodgers; Lara Kevorkian; Alison K Surridge; Jasmine G Waters; Tracey E Swingler; Kirsty Culley; Sara Illman; Jouko Lohi; Andrew E Parker; Ian M Clark
Journal:  Matrix Biol       Date:  2009-04-16       Impact factor: 11.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.